

SUPPLEMENTAL MATERIAL

Table S1. Hazard ratios of incident PAD and CLI, multiplicative and additive interaction (95% confidence intervals) of American Heart Association-defined intermediate physical activity level with demographic and clinical conditions.

	Intermediate vs. Poor physical activity	β_3	P- values	RERI	P-values
PAD					
Sex					
Male	1.01 (0.71-1.44)				
Female	0.89 (0.63-1.27)	-0.12 (-0.61-0.36)	0.615	-0.13 (-0.62-0.37)	0.618
Race					
White	1.02 (0.76-1.38)				
Black	0.79 (0.48-1.29)	-0.25 (-0.82-0.31)	0.380	-0.32 (-0.99-0.35)	0.343
Age					
<55	0.63 (0.42-0.93)*				
≥ 55	1.33 (0.95-1.84)	0.75 (0.25-1.25)*	0.003	0.68 (0.25-1.11)*	0.002
Ever smoking					
No	0.79 (0.48-1.28)				
Yes	1.02 (0.76-1.37)	0.25 (-0.30-0.80)	0.372	0.25 (-0.53-1.03)	0.531
Diabetes					
No	1.00 (0.74-1.35)				
Yes	0.86 (0.55-1.34)	-0.15 (-0.68-0.38)	0.578	-0.56 (-2.18-1.06)	0.495
Hypertension					
No	1.22 (0.86-1.72)				
Yes	0.70 (0.47-1.02)	-0.56 (-1.06--0.06)*	0.028	-0.57 (-1.08--0.06)*	0.027

(Continue Table S1)

CLI					
Sex					
Male		1.02 (0.55-1.90)			
Female		0.71 (0.40-1.28)	-0.36 (-1.19-0.46)	0.392	-0.35 (-1.16-0.46) 0.394
Race					
White		1.06 (0.62-1.82)			
Black		0.54 (0.24-1.20)	-0.68 (-1.63-0.27)	0.163	-1.02 (-2.15-0.11) 0.076
Age					
<55		0.72 (0.37-1.37)			
≥55		0.95 (0.55-1.67)	0.29 (-0.54-1.12)	0.495	0.23 (-0.55-1.01) 0.563
Ever smoking					
No		0.69 (0.34-1.38)			
Yes		0.95 (0.56-1.61)	0.32 (-0.53-1.17)	0.460	0.23 (-0.68-1.14) 0.620
Diabetes					
No		0.76 (0.42-1.40)			
Yes		0.92 (0.51-1.66)	0.19 (-0.63-1.01)	0.650	-0.34 (-4.50-3.83) 0.874
Hypertension					
No		1.22 (0.65-2.30)			
Yes		0.60 (0.33-1.10)	-0.71 (-1.56-0.14)	0.102	-0.85 (-1.84-0.13) 0.088

* Statistically significant at 5%

† All models adjusted for age, sex, race, education, smoking status, drinking status, health insurance, leisure score, work score, body mass index, systolic blood pressure, total and HDL cholesterol, creatinine-derived eGFR, white blood cell, diabetes, antihypertensive medication use, cholesterol-lowering medication use, aspirin use, and interaction term


‡ β_3 , coefficient of interaction term; RERI, relative excess risk for interaction

§ PAD, peripheral artery disease; CLI, critical limb ischemia; Poor physical activity: 0 min/week of moderate or vigorous exercise; Intermediate physical activity: 1-74 min/week of vigorous exercise or 1-149 min/week of moderate plus vigorous exercise

Table S2. Hazard ratios of incident PAD and CLI, multiplicative and additive interaction (95% confidence intervals) of per 200 METS*mins/week increase in vigorous physical activity with demographic and clinical conditions.

	Per 200 METS score increase in vigorous physical activity	β_3	P- values	RERI	P- values
PAD					
Sex					
Male	0.97 (0.90-1.04)				
Female	0.84 (0.70-1.01)	-0.14 (-0.33-0.06)	0.163	-0.11 (-0.26-0.04)	0.165
Race					
White	0.95 (0.89-1.02)				
Black	0.88 (0.73-1.06)	-0.08 (-0.28-0.12)	0.444	-0.12 (-0.37-0.12)	0.327
Age					
<55	0.94 (0.86-1.02)				
≥ 55	0.94 (0.85-1.04)	0.01 (-0.12-0.14)	0.906	-0.01 (-0.15-0.14)	0.915
Ever smoking					
No	0.94 (0.83-1.07)				
Yes	0.94 (0.87-1.01)	-0.01 (-0.15-0.14)	0.942	-0.08 (-0.29-0.12)	0.429
Diabetes					
No	0.96 (0.89-1.02)				
Yes	0.80 (0.62-1.04)	-0.18 (-0.45-0.09)	0.190	-0.68 (-1.43-0.08)	0.081
Hypertension					
No	0.95 (0.88-1.03)				
Yes	0.91 (0.80-1.03)	-0.05 (-0.20-0.10)	0.498	-0.03 (-0.15-0.09)	0.601

(Continue Table S2)



* Statistically significant at 5%

† All models adjusted for age, sex, race, education, smoking status, drinking status, health insurance, leisure score, work score, body mass index, systolic blood pressure, total and HDL cholesterol, creatinine-derived eGFR, white blood cell, diabetes, antihypertensive medication use, cholesterol-lowering medication use, aspirin use, and

interaction term

‡ β_3 , coefficient of interaction term; RERI, relative excess risk for interaction

§ PAD, peripheral artery disease; CLI, critical limb ischemia

Table S3. Hazard Ratios (95% Confidence Interval) for associations between American Heart Association-defined physical activity category with incident PAD and CLI with adjustment on baseline ABI category.

AHA-defined Physical Activity categories	Number of participants	Number of events	model 1†	model 2‡	model 3§	model 4 	model 5#
PAD							
Poor	4656	193	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
Intermediate	3096	101	0.74 (0.58-0.94)*	0.81 (0.63-1.03)	0.92 (0.72-1.18)	0.91 (0.71-1.17)	0.94 (0.73-1.21)
Recommended	4761	140	0.68 (0.54-0.84)*	0.69 (0.55-0.87)*	0.84 (0.67-1.06)	0.83 (0.65-1.05)	0.84 (0.66-1.07)
CLI							
Poor	4656	88	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
Intermediate	3096	32	0.51 (0.34-0.76)*	0.65 (0.43-0.98)*	0.76 (0.50-1.15)	0.77 (0.50-1.17)	0.83 (0.54-1.26)
Recommended	4761	46	0.49 (0.34-0.70)*	0.62 (0.42-0.89)*	0.77 (0.52-1.12)	0.79 (0.53-1.18)	0.81 (0.54-1.21)

* Statistically significant at 5%

† Model 1: Baseline ABI category

‡ Model 2: + Age, sex, race

§ Model 3: + Education, smoking status, drinking status, and health insurance

|| Model 4: + Leisure score and work score

Model 5: + Body mass index, systolic blood pressure, total and HDL cholesterol, creatinine-derived eGFR, white blood cell, diabetes, antihypertensive medication use, cholesterol-lowering medication use, and aspirin use

** PAD, peripheral artery disease; CLI, critical limb ischemia; AHA, American Heart Association

†† Poor: 0 min/week of moderate or vigorous exercise; Intermediate: 1-74 min/week of vigorous exercise or 1-149 min/week of moderate plus vigorous exercise;

Recommended: ≥ 75 min/week of vigorous exercise or ≥ 150 min/week of moderate plus vigorous exercise

Table S4. Hazard Ratios (95% Confidence Interval) of incident PAD and CLI per 200 METS*mins/week increase in moderate or vigorous physical activity with adjustment on baseline ABI category.

Physical activity intensity	model 1†	model 2‡	model 3§	model 4	model 5#
PAD					
Moderate	0.99 (0.95-1.02)	0.98 (0.95-1.02)	1.00 (0.96-1.03)	1.00 (0.96-1.03)	1.00 (0.96-1.03)
Vigorous	0.89 (0.83-0.95) *	0.90 (0.84-0.96) *	0.93 (0.87-0.99) *	0.93 (0.87-0.99) *	0.95 (0.89-1.02)
CLI					
Moderate	0.95 (0.90-1.01)	0.97 (0.92-1.03)	0.99 (0.94-1.05)	1.00 (0.94-1.06)	1.00 (0.94-1.06)
Vigorous	0.60 (0.43-0.84) *	0.65 (0.47-0.89) *	0.69 (0.51-0.93) *	0.70 (0.52-0.94) *	0.72 (0.53-0.97) *

* Statistically significant at 5%

† Model 1: Baseline ABI category

‡ Model 2: + Age, sex, race

§ Model 3: + Education, smoking status, drinking status, and health insurance

|| Model 4: + Leisure score and work score

Model 5: + Body mass index, systolic blood pressure, total and HDL cholesterol, creatinine-derived eGFR, white blood cell, diabetes, antihypertensive medication use, cholesterol-lowering medication use, and aspirin use

** PAD, peripheral artery disease; CLI, critical limb ischemia

Table S5. Hazard Ratios (95% Confidence Interval) for associations between American Heart Association-defined physical activity category with incident PAD and CLI with additional censoring on incident cardiovascular diseases.

AHA-defined Physical Activity categories	Number of participants	Number of events	model 1†	model 2‡	model 3§	model 4 	model 5#
PAD							
Poor	4656	168	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
Intermediate	3096	93	0.78 (0.60-0.99) *	0.84 (0.65-1.08)	0.96 (0.74-1.24)	0.95 (0.73-1.23)	0.98 (0.75-1.28)
Recommended	4761	130	0.70 (0.56-0.89) *	0.71 (0.56-0.90) *	0.87 (0.68-1.11)	0.85 (0.66-1.09)	0.87 (0.67-1.12)
CLI							
Poor	4656	74	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
Intermediate	3096	27	0.51 (0.33-0.79) *	0.63 (0.41-0.99) *	0.75 (0.47-1.17)	0.76 (0.48-1.21)	0.84 (0.53-1.33)
Recommended	4761	43	0.53 (0.36-0.77) *	0.65 (0.44-0.96) *	0.82 (0.55-1.22)	0.86 (0.57-1.31)	0.90 (0.59-1.38)

* Statistically significant at 5%

† Model 1: Crude model

‡ Model 2: + Age, sex, race

§ Model 3: + Education, smoking status, drinking status, and health insurance

|| Model 4: + Leisure score and work score

Model 5: + Body mass index, systolic blood pressure, total and HDL cholesterol, creatinine-derived eGFR, white blood cell, diabetes, antihypertensive medication use, cholesterol-lowering medication use, and aspirin use

** PAD, peripheral artery disease; CLI, critical limb ischemia; AHA, American Heart Association

†† Poor: 0 min/week of moderate or vigorous exercise; Intermediate: 1-74 min/week of vigorous exercise or 1-149 min/week of moderate plus vigorous exercise;

Recommended: ≥ 75 min/week of vigorous exercise or ≥ 150 min/week of moderate plus vigorous exercise

Table S6. Hazard Ratios (95% Confidence Interval) of incident PAD and CLI per 200 METS*mins/week increase in moderate or vigorous physical activity with additional censoring on incident cardiovascular diseases.

Physical activity intensity	model 1†	model 2‡	model 3§	model 4	model 5#
PAD					
Moderate	0.99 (0.95-1.02)	0.98 (0.94-1.02)	1.00 (0.96-1.03)	0.99 (0.96-1.03)	0.99 (0.96-1.03)
Vigorous	0.90 (0.84-0.96) *	0.90 (0.84-0.97) *	0.94 (0.88-1.01)	0.94 (0.88-1.01)	0.96 (0.90-1.03)
CLI					
Moderate	0.96 (0.90-1.02)	0.97 (0.91-1.04)	1.00 (0.94-1.06)	1.00 (0.94-1.07)	1.01 (0.94-1.08)
Vigorous	0.63 (0.45-0.87) *	0.67 (0.49-0.91) *	0.71 (0.53-0.95) *	0.72 (0.54-0.97) *	0.74 (0.55-0.99) *

* Statistically significant at 5%

† Model 1: Crude model

‡ Model 2: + Age, sex, race

§ Model 3: + Education, smoking status, drinking status, and health insurance

|| Model 4: + Leisure score and work score

Model 5: + Body mass index, systolic blood pressure, total and HDL cholesterol, creatinine-derived eGFR, white blood cell, diabetes, antihypertensive medication use, cholesterol-lowering medication use, and aspirin use

** PAD, peripheral artery disease; CLI, critical limb ischemia

Table S7. Hazard Ratios (95% Confidence Interval) for associations between American Heart Association-defined physical activity category with incident PAD and CLI with lag years.

AHA-defined Physical Activity categories	Number of participants	Number of events	model 1†	model 2‡	model 3§	model 4 	model 5 #
Lag 1 year							
PAD							
Poor	4654	191	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
Intermediate	3096	101	0.74 (0.58-0.95) *	0.81 (0.64-1.04)	0.94 (0.74-1.21)	0.93 (0.72-1.19)	0.96 (0.74-1.23)
Recommended	4759	138	0.66 (0.53-0.82) *	0.68 (0.54-0.85) *	0.85 (0.67-1.07)	0.82 (0.64-1.05)	0.84 (0.66-1.08)
CLI							
Poor	4654	88	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
Intermediate	3096	32	0.51 (0.34-0.76) *	0.64 (0.43-0.97) *	0.77 (0.51-1.16)	0.77 (0.51-1.18)	0.82 (0.53-1.25)
Recommended	4759	46	0.48 (0.33-0.68) *	0.60 (0.42-0.87) *	0.78 (0.53-1.14)	0.79 (0.53-1.18)	0.81 (0.54-1.21)
Lag 2 years							
PAD							

Poor	4654	191	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
Intermediate	3096	101	0.74 (0.58-0.94) *	0.82 (0.64-1.04)	0.94 (0.74-1.21)	0.93 (0.72-1.20)	0.96 (0.75-1.24)
Recommended	4755	134	0.64 (0.51-0.80) *	0.66 (0.53-0.83) *	0.82 (0.65-1.04)	0.80 (0.63-1.03)	0.82 (0.64-1.05)
CLI							
Poor	4654	88	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
Intermediate	3096	32	0.51 (0.34-0.76) *	0.64 (0.43-0.97) *	0.77 (0.51-1.16)	0.77 (0.51-1.18)	0.82 (0.53-1.25)
Recommended	4755	46	0.48 (0.33-0.68) *	0.60 (0.42-0.87) *	0.78 (0.53-1.14)	0.79 (0.53-1.18)	0.81 (0.54-1.21)

Lag 3 years

PAD							
Poor	4651	188	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
Intermediate	3096	101	0.75 (0.59-0.96) *	0.83 (0.65-1.06)	0.96 (0.75-1.23)	0.95 (0.74-1.22)	0.98 (0.76-1.26)
Recommended	4754	133	0.65 (0.52-0.81) *	0.67 (0.53-0.84) *	0.83 (0.66-1.05)	0.81 (0.63-1.04)	0.83 (0.65-1.07)
CLI							
Poor	4651	86	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
Intermediate	3096	32	0.52 (0.35-0.78) *	0.66 (0.44-1.00)	0.78 (0.52-1.19)	0.79 (0.52-1.21)	0.84 (0.55-1.30)

Recommended	4754	46	0.49 (0.34-0.70) *	0.62 (0.43-0.90) *	0.80 (0.54-1.17)	0.82 (0.55-1.22)	0.84 (0.56-1.25)
--------------------	------	----	--------------------	--------------------	------------------	------------------	------------------

Lag 4 years

PAD

Poor	4649	186	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
Intermediate	3093	98	0.74 (0.58-0.94) *	0.81 (0.63-1.04)	0.94 (0.73-1.21)	0.93 (0.72-1.20)	0.97 (0.75-1.25)
Recommended	4753	132	0.65 (0.52-0.81) *	0.67 (0.53-0.85) *	0.83 (0.66-1.06)	0.82 (0.64-1.05)	0.85 (0.66-1.09)

CLI

Poor	4649	86	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
Intermediate	3093	31	0.50 (0.33-0.76) *	0.64 (0.42-0.97) *	0.76 (0.50-1.16)	0.77 (0.50-1.17)	0.82 (0.53-1.26)
Recommended	4753	46	0.49 (0.34-0.70) *	0.62 (0.43-0.90) *	0.79 (0.54-1.16)	0.81 (0.54-1.21)	0.84 (0.56-1.25)

Lag 5 years

PAD

Poor	4646	183	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
Intermediate	3092	97	0.74 (0.58-0.95) *	0.82 (0.64-1.05)	0.95 (0.74-1.22)	0.94 (0.73-1.22)	0.98 (0.75-1.26)

Recommended	4751	130	0.65 (0.52-0.81) *	0.67 (0.53-0.85) *	0.83 (0.66-1.06)	0.83 (0.64-1.06)	0.85 (0.66-1.10)
CLI							
Poor	4646	84	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
Intermediate	3092	31	0.52 (0.34-0.78) *	0.66 (0.43-1.00)	0.78 (0.51-1.19)	0.79 (0.51-1.21)	0.85 (0.55-1.31)
Recommended	4751	46	0.50 (0.35-0.72) *	0.64 (0.44-0.93) *	0.82 (0.56-1.20)	0.84 (0.56-1.25)	0.86 (0.57-1.29)

* Statistically significant at 5%

† Model 1: Crude model

‡ Model 2: + Age, sex, race

§ Model 3: + Education, smoking status, drinking status, and health insurance

|| Model 4: + Leisure score and work score

Model 5: + Body mass index, systolic blood pressure, total and HDL cholesterol, creatinine-derived eGFR, white blood cell, diabetes, antihypertensive medication use, cholesterol-lowering medication use, and aspirin use

** PAD, peripheral artery disease; CLI, critical limb ischemia; AHA, American Heart Association

†† Poor: 0 min/week of moderate or vigorous exercise; Intermediate: 1-74 min/week of vigorous exercise or 1-149 min/week of moderate plus vigorous exercise;

Recommended: ≥ 75 min/week of vigorous exercise or ≥ 150 min/week of moderate plus vigorous exercise

Table S8. Hazard Ratios (95% Confidence Interval) of incident PAD and CLI per 200 METS*mins/week increase in moderate or vigorous physical activity with lag years.

Physical activity intensity	model 1†	model 2‡	model 3§	model 4 	model 5#
Lag 1 year					
PAD					
Moderate	0.98 (0.94-1.01)	0.98 (0.94-1.01)	1.00 (0.96-1.03)	0.99 (0.96-1.03)	1.00 (0.96-1.03)
Vigorous	0.89 (0.83-0.95) *	0.90 (0.84-0.96) *	0.93 (0.87-1.00) *	0.93 (0.87-1.00) *	0.95 (0.89-1.02)
CLI					
Moderate	0.93 (0.88-0.99) *	0.96 (0.90-1.02)	0.99 (0.93-1.05)	0.99 (0.93-1.06)	1.00 (0.94-1.06)
Vigorous	0.59 (0.42-0.82) *	0.64 (0.47-0.88) *	0.69 (0.51-0.93) *	0.70 (0.52-0.94) *	0.72 (0.54-0.97) *
Lag 2 years					
PAD					
Moderate	0.97 (0.94-1.01)	0.97 (0.94-1.01)	0.99 (0.96-1.03)	0.99 (0.96-1.03)	0.99 (0.96-1.03)
Vigorous	0.89 (0.83-0.95) *	0.90 (0.84-0.96) *	0.93 (0.88-1.00) *	0.94 (0.88-1.00) *	0.95 (0.89-1.02)

CLI

Moderate	0.93 (0.88-0.99) *	0.96 (0.90-1.02)	0.99 (0.93-1.05)	0.99 (0.93-1.06)	1.00 (0.94-1.06)
Vigorous	0.59 (0.42-0.82) *	0.64 (0.47-0.88) *	0.69 (0.51-0.93) *	0.70 (0.52-0.94) *	0.72 (0.54-0.97) *

Lag 3 years

PAD

Moderate	0.98 (0.94-1.01)	0.97 (0.94-1.01)	1.00 (0.96-1.03)	1.00 (0.96-1.03)	1.00 (0.96-1.03)
Vigorous	0.89 (0.83-0.95) *	0.90 (0.84-0.96) *	0.94 (0.88-1.00) *	0.94 (0.88-1.00)	0.96 (0.89-1.02)

CLI

Moderate	0.94 (0.88-0.99) *	0.96 (0.91-1.02)	0.99 (0.93-1.05)	1.00 (0.94-1.06)	1.00 (0.94-1.07)
Vigorous	0.59 (0.42-0.83) *	0.64 (0.47-0.88) *	0.69 (0.51-0.93) *	0.70 (0.52-0.94) *	0.72 (0.54-0.97) *

Lag 4 years

PAD

Moderate	0.98 (0.94-1.01)	0.97 (0.94-1.01)	1.00 (0.96-1.03)	1.00 (0.96-1.03)	1.00 (0.96-1.04)
Vigorous	0.89 (0.83-0.95) *	0.90 (0.84-0.96) *	0.94 (0.88-1.00)	0.94 (0.88-1.00)	0.96 (0.90-1.02)

CLI

Moderate	0.93 (0.88-0.99) *	0.96 (0.91-1.02)	0.99 (0.93-1.05)	1.00 (0.94-1.06)	1.00 (0.94-1.07)
Vigorous	0.59 (0.42-0.83) *	0.64 (0.47-0.88) *	0.69 (0.51-0.93) *	0.70 (0.52-0.94) *	0.72 (0.54-0.97) *

Lag 5 years**PAD**

Moderate	0.98 (0.94-1.01)	0.98 (0.94-1.01)	1.00 (0.96-1.03)	1.00 (0.96-1.03)	1.00 (0.96-1.04)
Vigorous	0.89 (0.83-0.95) *	0.90 (0.84-0.96) *	0.94 (0.88-1.00)	0.94 (0.88-1.00)	0.96 (0.90-1.03)

CLI

Moderate	0.94 (0.88-1.00) *	0.97 (0.91-1.03)	0.99 (0.94-1.05)	1.00 (0.94-1.06)	1.00 (0.94-1.07)
Vigorous	0.59 (0.43-0.83) *	0.65 (0.47-0.88) *	0.69 (0.51-0.94) *	0.70 (0.52-0.95) *	0.73 (0.54-0.98) *

* Statistically significant at 5%

† Model 1: Crude model

‡ Model 2: + Age, sex, race

§ Model 3: + Education, smoking status, drinking status, and health insurance

|| Model 4: + Leisure score and work score

Model 5: + Body mass index, systolic blood pressure, total and HDL cholesterol, creatinine-derived eGFR, white blood cell, diabetes, antihypertensive medication use, cholesterol-lowering medication use, and aspirin use

** PAD, peripheral artery disease; CLI, critical limb ischemia

Table S9. Hazard Ratios (95% Confidence Interval) for associations between 5 physical activity categories regardless of intensity with incident PAD and CLI.

Physical Activity categories	Number of participants	Number of events	model 1†	model 2‡	model 3§	model 4 	model 5#
PAD							
0 min/week	4524	189	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
1-74 min/week	1251	35	0.64 (0.45-0.92)*	0.69 (0.48-0.99)*	0.78 (0.54-1.13)	0.77 (0.54-1.11)	0.80 (0.56-1.16)
75-149 min/week	1803	62	0.76 (0.57-1.01)	0.82 (0.62-1.10)	0.98 (0.73-1.32)	0.97 (0.72-1.30)	0.98 (0.73-1.33)
150-299 min/week	2872	88	0.69 (0.53-0.88)*	0.72 (0.56-0.93)*	0.90 (0.69-1.17)	0.88 (0.67-1.15)	0.87 (0.66-1.14)
≥300 min/week	2063	60	0.65 (0.49-0.87)*	0.65 (0.48-0.88)*	0.81 (0.60-1.09)	0.78 (0.57-1.07)	0.89 (0.65-1.22)
P-value for trend			<0.001	0.002	0.232	0.179	0.383
CLI							
0 min/week	4524	87	1(ref.)	1(ref.)	1(ref.)	1(ref.)	1(ref.)
1-74 min/week	1251	13	0.52 (0.29-0.92)*	0.62 (0.35-1.12)	0.73 (0.41-1.32)	0.73 (0.41-1.32)	0.79 (0.44-1.44)
75-149 min/week	1803	18	0.48 (0.29-0.79)*	0.60 (0.36-1.00)	0.73 (0.43-1.22)	0.74 (0.44-1.25)	0.79 (0.47-1.34)
150-299 min/week	2872	29	0.49 (0.32-0.75)*	0.62 (0.41-0.96)*	0.80 (0.51-1.24)	0.81 (0.52-1.27)	0.78 (0.49-1.22)

≥300 min/week	2063	19	0.44 (0.27-0.73)*	0.57 (0.34-0.95)*	0.73 (0.44-1.23)	0.75 (0.44-1.28)	0.93 (0.54-1.61)
P-value for trend			<0.001	0.006	0.157	0.216	0.408

* Statistically significant at 5%

† Model 1: Crude model

‡ Model 2: + Age, sex, race

§ Model 3: + Education, smoking status, drinking status, and health insurance

|| Model 4: + Leisure score and work score

Model 5: + Body mass index, systolic blood pressure, total and HDL cholesterol, creatinine-derived eGFR, white blood cell, diabetes, antihypertensive medication use, cholesterol-lowering medication use, and aspirin use

** PAD, peripheral artery disease; CLI, critical limb ischemia